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Introduction {#sec1}
============

A recurring feature in malignant cancers is the aggressive alterations that cells undergo in order to survive in a low-oxygen (hypoxic) environment. This hypoxic environment is commonly a result of insufficient tumor vascularity and is strongly associated with increased radioresistance, chemoresistance, and metastasis ([@bib42], [@bib46], [@bib55]). Among those cancers with a propensity for high levels of tumor hypoxia, pancreatic ductal adenocarcinoma (PDAC) has a well-established hypoxic signature, which is predictive of poorer patient prognosis ([@bib6], [@bib31]). PDAC has a poor 5-year survival of less than 8% and is predicted to be the second leading cause of cancer-related deaths by 2030 ([@bib38], [@bib45]). One approach to improve patient outcome has been to target hypoxic tumor regions in order to improve both drug penetrance and response ([@bib7], [@bib47]). Hypoxia-activated pro-drugs (HAPs) provide an efficient method to specifically deliver cytotoxic agents to hypoxic tumor regions, diminishing the off-target effects from conventional small-molecule therapeutics ([@bib34], [@bib55]). These HAPs may also affect normoxic tumor regions by virtue of a local bystander effect and in this way provide an even more versatile approach for targeted delivery ([@bib1], [@bib47]). Cytotoxic mustard-based HAPs, such as TH-302 ([@bib29], [@bib47]) and PR-104 ([@bib1]), are currently the most widely applied, building on the ushering work of tirapazamine and related derivatives ([@bib26], [@bib55]). Recently, we have seen an emergence of bioreductive groups attached to targeted therapeutics, concomitant with improvements in their synthesis and sensitivity ([@bib34], [@bib55]). However, HAPs are generally insufficient for use as monotherapies, and current clinical trials focus on their application in combination with chemotherapeutics, radiotherapy, or targeted therapies ([@bib4], [@bib49], [@bib55]).

In recent work, we demonstrated that targeting of the phosphatidylinositol 3-kinase (PI3K) pathway with the dual mTORC1/2 inhibitor AZD2014 presents a therapeutic opportunity for PDAC, equivalent to the standard-of-care gemcitabine ([@bib10]). This built upon our previous work, whereby the mTORC1 inhibitor rapamycin showed improved efficacy in tumors with high PI3K pathway activity ([@bib23], [@bib32]). There is a well-established role for the PI3K pathway in hypoxia, which is linked with chemoresistance, metabolic reprogramming, and angiogenesis ([@bib5], [@bib15]). Here, we identify a phenomenon whereby two aggressive PDAC models were resistant to three clinically relevant PI3K pathway inhibitors, when grown in a hypoxic environment. We investigate this resistance within a three-dimensional (3D) organotypic co-culture system ([@bib8], [@bib33], [@bib51]) and confirm that resistance to PI3K pathway inhibition only occurred in hypoxic cells invading into the matrix. Furthermore, we reveal that hypoxia moves transiently around the tumor *in vivo* and this pocket of resistance presents a potential moving target in PDAC.

To combat this hypoxia-induced resistance, we developed a combination therapy that combines the dual PI3K pathway inhibitor AZD2014 with the HAP TH-302. This combination reduces the hypoxia-induced resistance to AZD2014 *in vitro* and significantly inhibits tumor growth *in vivo*. To elucidate the improved outcomes from this combination therapy, we performed live intravital microscopy (IVM) of drug-target activity using an intramolecular Förster resonance energy transfer (FRET) biosensor for Akt activity ([@bib24]). Monitoring drug response in individual cells by fluorescence lifetime imaging microscopy (FLIM)-FRET, in parallel with phosphorescence lifetime imaging microscopy (PLIM) of oxygen-sensitive nanoparticles ([@bib9], [@bib25]), enabled the stratification of single-cell responses within different tumor compartments. This demonstrated that regions with poorer drug response also had lower oxygen content. Furthermore, when tumor-bearing mice were treated in combination with the HAP TH-302 and AZD2014, Akt activity was further reduced, compared to AZD2014 monotherapy. Critically, these findings highlight both the value of combining targeted therapeutics with HAPs and the preclinical power of IVM in the drug discovery pipeline ([@bib8], [@bib30]).

Results {#sec2}
=======

Hypoxia Induces Resistance to PI3K Pathway Inhibition in PDAC {#sec2.1}
-------------------------------------------------------------

Hypoxia is a common feature of PDAC and are often associated with malignant disease ([@bib6], [@bib31]). Hypoxia is regularly the result of a disorganized vascular network within the tumor and, in the extreme case of anoxia (no oxygen), may lead to necrosis ([@bib55]). To investigate the role of hypoxia in PDAC, we used the well-established non-invasive *LSL-Kras*^*G12D/+*^*, LSL-Trp53*^*fl/+*^*, Pdx1-Cre* (KP^fl^C) and invasive *LSL-Kras*^*G12D/+*^*, LSL-Trp53*^*R172H/+*^*, Pdx1-Cre* (KPC) genetically engineered mouse (GEM) models ([@bib17], [@bib18], [@bib33]). These PDAC models possess driver mutations in *Kras* and loss or gain-of-function mutation of the tumor suppressor gene *Trp53*, which occur in ∼95% and ∼75% of human PDAC cases, respectively ([@bib18], [@bib33], [@bib52]). This altered p53 function has been associated with improved survival of cancer cells in hypoxic conditions ([@bib27]). However, we found no significant difference in the fraction of Ki67-positive cells between hypoxic and normoxic regions of tumors in either model, as stratified by pimonidazole staining ([Figure S1](#mmc1){ref-type="supplementary-material"}A; quantified in [Figure S1](#mmc1){ref-type="supplementary-material"}B) ([@bib50]). Importantly, we observed a significant upregulation in Akt activity in hypoxic regions of the GEM PDAC models ([Figure 1](#fig1){ref-type="fig"}A; quantified in [Figure 1](#fig1){ref-type="fig"}B), in line with previous reports ([@bib5], [@bib15]).Figure 1The Presence of Hypoxia and the Associated Molecular, Phenotypic, and Resistance Effects in the KP^fl^C and KPC Mouse Models of PDAC(A) Immunofluorescence staining of the GEM KP^fl^C and KPC PDAC mouse models for Akt(Ser473) (red), DAPI (cyan), and pimonidazole (green). Scale bars, 50 μm.(B) Quantification of Akt(Ser473) grey value/cell in pimonidazole negative (normoxic) and positive (hypoxic) regions (n = 5 tumors/mouse model). Mean ± SEM. p values are from a one-sample t test.(C) Propidium iodide staining of cell cycle phase distribution in the KP^fl^C and KPC primary PDAC cell lines. Mean ± SEM. p values were calculated using a two-way ANOVA with a Tukey correction for multiple comparisons.(D) Representative western blots of the KP^fl^C and KPC primary PDAC cell lines, incubated for 48 hr in normoxia or hypoxia (5%, 1%, or 0.1% oxygen; n = 5).(E) A simplified schematic of the PI3K pathway, indicating the targets of the PI3K pathway inhibitors used in this study.(F and G) IC~50~ curves demonstrating the response of KP^fl^C (F) and KPC (G) primary PDAC cell lines to the PI3K pathway inhibitors rapamycin, NVP-BEZ235, and AZD2014, in both normoxic (black lines) and hypoxic (0.1% oxygen, red lines) conditions (n = 3). An extra sum-of-squares F test was performed between the best-fit parameters of each curve.^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Primary cell lines with loss or gain of function of p53 ([Figure S1](#mmc1){ref-type="supplementary-material"}C), previously isolated from both PDAC mouse models, were assessed for their response to hypoxia at 5%, 1%, and 0.1% oxygen ([@bib33]). A small decrease in S phase at decreasing oxygen levels was observed for both cell lines when performing cell cycle analysis by fluorescence-activated cell sorting (FACS) ([Figure 1](#fig1){ref-type="fig"}C). To assess whether the slight reduction in S phase conferred a decrease in cell number, we quantified cells in 0.1% oxygen and found no significant decrease in cell number, compared to normoxia ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Furthermore, decreasing oxygen levels were not found to have a significant effect on apoptosis in either of the PDAC cell lines, assessed by Annexin V staining ([Figure S1](#mmc1){ref-type="supplementary-material"}E).

As anticipated, we observed a significant increase in HIF1α stabilization at 5%, 1%, and 0.1% oxygen ([Figure 1](#fig1){ref-type="fig"}D; quantified in [Figure S1](#mmc1){ref-type="supplementary-material"}F), and a graded increase in pimonidazole adduct formation ([Figure S1](#mmc1){ref-type="supplementary-material"}G; quantified in [Figure S1](#mmc1){ref-type="supplementary-material"}H). Having established a hypoxic response, we assessed the activity of the PI3K pathway and identified a significant upregulation of Akt activity in hypoxia in both cell lines ([Figure 1](#fig1){ref-type="fig"}D; quantified in [Figures S1](#mmc1){ref-type="supplementary-material"}I and S1J). Conversely, looking downstream of mTORC1, phosphorylation of p70-S6K was significantly reduced, consistent with previous reports ([Figure 1](#fig1){ref-type="fig"}D; quantified in [Figure S1](#mmc1){ref-type="supplementary-material"}K) ([@bib13]). These data confirm a role for the PI3K pathway in the hypoxic response within our models and prompted assessment of therapeutic inhibition of the PI3K pathway within this hypoxic environment.

We employed three clinically relevant inhibitors of the PI3K pathway, namely, rapamycin, NVP-BEZ235, and AZD2014 ([Figure 1](#fig1){ref-type="fig"}E). These inhibitors allowed us to target multiple levels of the PI3K pathway to provide a broader assessment of therapeutic response ([Figures 1](#fig1){ref-type="fig"}E--1G). Evaluating the half-maximal inhibitory concentration (IC~50~) for each inhibitor in both hypoxia and normoxia, we found that primary PDAC cell lines from each model showed hypoxia-induced resistance to all three PI3K pathway-targeted therapeutics ([Figures 1](#fig1){ref-type="fig"}F and 1G).

3D Assessment of Hypoxia-Induced Resistance in Invasive KPC PDAC Cells {#sec2.2}
----------------------------------------------------------------------

The KPC PDAC model recapitulates the invasive and metastatic phenotype that is frequently observed in the clinical management of this disease ([@bib17], [@bib18], [@bib33]). We therefore used 3D organotypic invasion assays to assess the effects of targeting the PI3K pathway in the invasive KPC cells ([@bib8], [@bib33], [@bib51]). To confirm the presence of hypoxia within our 3D organotypic matrices, KPC cells were seeded and allowed to grow on fibroblast-contracted matrices for 4 days before mounting the matrices on an air-liquid interface, which promotes invasion toward the chemo-attractive media ([Figure 2](#fig2){ref-type="fig"}A) ([@bib8], [@bib33], [@bib51]). Interestingly, staining for hypoxia within the organotypic matrices demonstrated a clear gradient of decreasing oxygen content from the surface of the matrix (see "Normoxia," [Figure 2](#fig2){ref-type="fig"}A) to the invading cells within the matrix (see "Hypoxia," [Figure 2](#fig2){ref-type="fig"}A). To confirm that this gradient was not a result of poor diffusion of pimonidazole into the matrix, we treated organotypic matrices with the fluorescent probe laurdan, as well as the autofluorescent drug doxorubicin ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). In both cases, fluorescence of each compound was visible in cells on the surface and within the matrix ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). To further corroborate the presence of a hypoxic gradient, we stained our organotypics for expression of GLUT1 and lactate dehydrogenase ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). These proteins are typically upregulated under hypoxic conditions and were found to be upregulated in hypoxia (5%, 1%, and 0.1% oxygen) in the KPC cells ([Figure S2](#mmc1){ref-type="supplementary-material"}E; quantified in [Figure S2](#mmc1){ref-type="supplementary-material"}F) ([@bib44]).Figure 2Organotypic Invasion Assay of KPC Cells Treated with PI3K Pathway Inhibitors and/or TH-302(A) A schematic representation of the organotypic matrix assay and a representative area of invading KPC cells stained with pimonidazole (a marker of hypoxia).(B) Representative images of invading KPC cells stained with the epithelial cell marker pan-cytokeratin or the proliferative marker Ki67. Scale bars, 100 μm; insets, 25 μm.(C) Normalized Ki67 staining from the same experiments scored for cells on top of the organotypic matrix (normoxia) and cells invading into the matrix (hypoxia). Mean ± SEM.(D) Normalized invasive index of KPC cells treated with NVP-BEZ235, AZD2014, or rapamycin (n = 3). Mean ± SEM.(E and F) Representative images of invading KPC cells stained with the hypoxia marker pimonidazole (E) or the proliferative marker Ki67 (F). Scale bars, 50 μm; insets, 10 μm. Mean ± SEM.(G) Quantification of Ki67-stained KPC cells invading into organotypic matrices (n=4).(H and I) Assessment of Ki67-stained KPC cells either on top of (H, normoxia) or invading into (I, hypoxia) organotypic matrices (n = 4). A one-sample t test was performed on normalized data in all panels.^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Next, cells invading into organotypic matrices were treated with each PI3K pathway inhibitor ([Figure 2](#fig2){ref-type="fig"}B). Supporting our IC~50~ curves, the cells on the surface of the matrix ("Normoxia") demonstrated a significant reduction in Ki67 staining for all inhibitors, while cells invading into the organotypic matrices ("Hypoxia") were resistant to the inhibitors ([Figure 2](#fig2){ref-type="fig"}B, inset: see blue arrows and note reduction in Ki67-positive cells in normoxia for all inhibitors, which was less evident in hypoxia \[see red arrows\]; quantified in [Figure 2](#fig2){ref-type="fig"}C). Furthermore, treatment with rapamycin and NVP-BEZ235 yielded a subtle yet significant decrease in invasion, while AZD2014 induced a robust anti-invasive effect ([Figure 2](#fig2){ref-type="fig"}B; quantified in [Figure 2](#fig2){ref-type="fig"}D). Taken together, we found a common hypoxia-induced resistance to PI3K pathway targeting within our 3D organotypic matrices.

Therapeutic Response of PDAC Cells Treated with AZD2014 Is Improved by the HAP TH-302 {#sec2.3}
-------------------------------------------------------------------------------------

After confirming the hypoxia-induced resistance to PI3K pathway inhibition within the 3D organotypic assay, we chose to combat this resistance in a combination therapy. An attractive option for targeting the resistant hypoxic compartment is through the use of HAPs, which provide additional benefits with minimal toxicity to normoxic tissues ([@bib1], [@bib29], [@bib55]). We selected the dual mTORC1/2 inhibitor AZD2014 to develop a combination therapy with the HAP TH-302. TH-302 has already been shown to improve mTOR-targeted therapies in renal cell carcinoma ([@bib47]), and within our models, AZD2014 alone has demonstrated a clear survival benefit, equivalent to that of gemcitabine ([@bib10]). Here, we identified an additional anti-invasive effect provided by AZD2014 ([Figure 2](#fig2){ref-type="fig"}D, see blue bar), which may address the clinical need to reduce invasion and metastasis in PDAC patients. We next assessed the effect of TH-302 alone on KPC cells ([Figure S2](#mmc1){ref-type="supplementary-material"}G). As expected, TH-302 showed a greatly reduced IC~50~ in hypoxia, compared to normoxia, consistent with an increased potency in hypoxia ([Figure S2](#mmc1){ref-type="supplementary-material"}G) ([@bib29]). We then assessed the effect of TH-302 on the hypoxia-induced resistance of AZD2014 ([Figures 2](#fig2){ref-type="fig"}E--2I). Having established the presence of a hypoxic gradient within our organotypic matrices ([Figure 2](#fig2){ref-type="fig"}A), we assessed the effect of combining TH-302 with AZD2014 in a 3D environment ([Figures 2](#fig2){ref-type="fig"}E and 2F). In combination, the anti-proliferative effects of both inhibitors were significantly improved overall ([Figure 2](#fig2){ref-type="fig"}G, compare red and blue bars to green). Upon further analysis, we found hypoxia-induced resistance to AZD2014 for cells within the matrix (Hypoxia), which was significantly reduced in combination with TH-302 ([Figure 2](#fig2){ref-type="fig"}F, inset: see red arrows). In contrast, TH-302 treatment led to a 50% decrease in Ki67-positive cells within the matrix (Hypoxia), which did not occur on the surface of the matrix ([Figure 2](#fig2){ref-type="fig"}F, inset, see red/blue arrows; [Figures 2](#fig2){ref-type="fig"}H and 2I, compare black bars to red). Furthermore, we assessed the effect of AZD2014 on the PI3K pathway by staining matrices for the downstream stress response gene NDRG1(Thr346). This staining highlighted a significant downregulation of NDRG1 activity in the combination therapy, compared to AZD2014 alone ([Figure S2](#mmc1){ref-type="supplementary-material"}H). Consistent with a role in stress response, NDRG1 was also shown to be upregulated in decreasing oxygen levels ([Figure S2](#mmc1){ref-type="supplementary-material"}E; quantified in [Figure S2](#mmc1){ref-type="supplementary-material"}F), as well as in cells within the matrix ([Figure S2](#mmc1){ref-type="supplementary-material"}H, inset: compare frequently negatively stained cells on the surface of the matrix "Normoxia," to darkly stained cells within the matrix "Hypoxia"). Moreover, to confirm the activity of TH-302 within the matrix, γH2AX staining was performed and demonstrated a significant upregulation in DNA damage response within the organotypic matrices for TH-302 and the combination therapy ([Figure S2](#mmc1){ref-type="supplementary-material"}I). These data are consistent with the activity of TH-302 increasing within the lower oxygen environment of the organotypic matrix, where it plays a significant role in alleviating the overall hypoxia-induced resistance to AZD2014 ([Figures 2](#fig2){ref-type="fig"}F--2I).

*In Vivo* Assessment of Subcutaneous PDAC Tumors Treated with AZD2014 in Combination with the HAP TH-302 {#sec2.4}
--------------------------------------------------------------------------------------------------------

Guided by the spatial response of the combination therapy identified in our 3D organotypic matrices, we investigated whether this effect was recapitulated *in vivo*. KPC tumor-bearing mice were treated with a combination of AZD2014 (2.5 mg/kg) and TH-302 (50 mg/kg). Here, we observed a significant decrease in both tumor growth and Ki67 positivity within the combination-treated tumors, compared to AZD2014 monotherapy ([Figures 3](#fig3){ref-type="fig"}A--3C). Previous work has demonstrated that the DNA cross-linking effect of TH-302 is associated with an increase in γH2AX-positive cells, consistent with activation of the DNA damage response ([@bib29], [@bib47]). In agreement, TH-302 treatment resulted in a significant increase in γH2AX-positive cells in this study ([Figure 3](#fig3){ref-type="fig"}D). Interestingly, AZD2014 alone also caused a significant increase in γH2AX-positive cells, in line with the known role of the PI3K pathway in sensitizing cells to DNA damage ([Figure 3](#fig3){ref-type="fig"}D) ([@bib47]). Similarly, both the mono- and combination therapies showed an increase in necrosis, compared to vehicle treatment ([Figure 3](#fig3){ref-type="fig"}E). We concluded that both drugs were working as expected within the tumors, but the benefit of TH-302 combination therapy over AZD2014 monotherapy was not provided by an increased sensitization of cells to DNA damage.Figure 3Assessment of KPC Subcutaneous Xenografts Treated with TH-302 (50 mg/kg) and AZD2014 (2.5 mg/kg)(A and B) Tumor volume measurements (A) and average linear growth rate (B) of tumors over 7 days from vehicle/saline (n = 10), vehicle/TH-302 (n = 9), AZD2014/saline (n = 10), and AZD2014/TH-302 (n = 10).(C and D) Immunohistochemistry (IHC) staining of drug response in tumors assessed for the proliferative marker Ki67 (n = 5 tumors/treatment) (C) and DNA damage response (γH2AX, n = 5 tumors/treatment) (D). Scale bars, 100 μm; insets, 10 μm. Mean ± SEM.(E and F) Staining for the necrotic (using H&E) (E) and hypoxic (pimonidazole IHC) (F) tumor fractions from vehicle/saline (n = 10), vehicle/TH-302 (n = 9), AZD2014/saline (n = 10), and AZD2014/TH-302 (n = 10) treatments. Scale bars, 1 mm; insets, 100 μm. Mean ± SEM.(G) HIF1α (n = 5 tumors/treatment) IHC staining of tumors. Scale bars, 100 μm; insets, 10 μm. Mean ± SEM.(H) Carbonic anhydrase IX (CAIX) IHC staining of tumors from vehicle/saline (n = 10), vehicle/TH-302 (n = 9), AZD2014/saline (n = 10), and AZD2014/TH-302 (n = 10) treatments. Scale bars, 100 μm; insets, 10 μm. Mean ± SEM. p values are from a Student two-tailed parametric t test in all panels.^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

We then assessed whether the reduced fraction of Ki67-positive cells between AZD2014 alone or in combination with TH-302 ([Figure 3](#fig3){ref-type="fig"}C) was due to a reduction in the hypoxic burden of the tumor. Assessing the hypoxic fraction of the tumors by pimonidazole staining, we observed a significant decrease between AZD2014 alone and the combination ([Figure 3](#fig3){ref-type="fig"}F, compare blue bar to green). This modest change seemed unlikely to be the only factor involved in the observed differences between the treatments. Moreover, it is important to note that pimonidazole is a marker of very low oxygen content and does not always coincide with the subtle changes in hypoxic response pathways within the cell ([Figures S1](#mmc1){ref-type="supplementary-material"}G and S1H) ([@bib50], [@bib55]). To assess this more directly, we stained for HIF1α, which is responsible for mounting much of the cellular hypoxic response. This staining revealed a significant decrease in the fraction of cells actively responding to a low oxygen environment, in both TH-302 alone and combination treatments ([Figure 3](#fig3){ref-type="fig"}G). Furthermore, staining for carbonic anhydrase IX (CAIX), an important downstream component of the cellular pH-regulatory response in hypoxia ([@bib37]), coincided with a significant decrease in CAIX expression in the mono- and combination therapies ([Figure 3](#fig3){ref-type="fig"}H). Additionally, to assess whether the derived benefit of the combination was a result of changes in vasculature, we quantified the coverage of microvessels stained for CD31 and found no significant difference between the treatments ([Figure S3](#mmc1){ref-type="supplementary-material"}A).

While these changes may be acting additively to elicit the growth inhibition and decreased Ki67 positivity in the combination therapy, we also assessed whether there was a combined effect of each treatment on the cell cycle. Initially, we scored the number of cells with fragmented nuclei in each condition and found a significant increase, which may indicate a higher rate of mitotic failure ([Figure S3](#mmc1){ref-type="supplementary-material"}B). This led us to assess the effect of our therapies on mitotic progression, through HistoneH3(Ser10) staining ([Figure 4](#fig4){ref-type="fig"}A). By this approach, we found a significant upregulation of HistoneH3(Ser10)-positive cells in the TH-302 treatments and a significant downregulation in the AZD2014 treatments ([Figure 4](#fig4){ref-type="fig"}A). Upon further phenotypic assessment of the specific stages, from late G~2~ through to anaphase, we found that TH-302 causes cells to accumulate in late G~2~ at the initiation of mitosis, observing increased focal staining of HistoneH3(Ser10) within nuclei ([Figures 4](#fig4){ref-type="fig"}B--4E) ([@bib16]). To confirm this effect *in vitro*, we performed FACS analysis of KPC cells treated with each inhibitor at 0.1% oxygen ([Figure 4](#fig4){ref-type="fig"}F). Here, we observed a significant arrest of TH-302-treated cells in G~2~/M, which we verified by observing HistoneH3(Ser10) accumulation ([Figure 4](#fig4){ref-type="fig"}G). TH-302 induces DNA damage in cells throughout the entire cell cycle, but our data suggest that in hypoxia TH-302-damaged cells arrest just prior to mitotic entry. This is likely to greatly enhance the mTORC1/2 inhibition of cells that escape this arrest ([Figure 4](#fig4){ref-type="fig"}H). Indeed, mTORC1 is independently regulated during mitosis and is required for efficient transit through the G~2~/M transition, and cytokinesis ([@bib40]). Furthermore, mTORC2 has been shown to be essential for S and G~2~/M cell cycle progression after treatment with a DNA-damaging agent ([@bib43]). This may partially explain the additive effect found in the combination therapy ([Figure 4](#fig4){ref-type="fig"}H). These readouts however, do not provide any details with regard to the treatment-induced modulation of PI3K pathway activity, within both the hypoxic and normoxic tumor compartments. We therefore chose to track the hypoxic tumor regions, as an initial step toward mapping drug response.Figure 4Characterization of the Cell Cycle Response of KPC Subcutaneous Xenografts Treated with TH-302 (50 mg/kg) and AZD2014 (2.5 mg/kg)(A) IHC staining of drug response in tumors assessed for the mitosis marker HistoneH3(Ser10) (n = 5 tumors/treatment). Scale bars, 100 μm; insets, 10 μm. Mean ± SEM. p values are from a Student two-tailed parametric t test.(B--E) Phenotypic quantification of four distinguishable stages of mitosis, namely late G~2~ (B), prophase (C), metaphase (D), and anaphase (E), where HistoneH3(Ser10) presents a unique phenotype. Scale bars, 10 μm. Mean ± SEM. p values are from a Student two-tailed parametric t test.(F) Propidium iodide staining of cell cycle phase distribution in KPC primary PDAC cells after treatment with AZD2014 (500 nM) and/or TH-302 (1 μM) at 0.1% oxygen. Mean ± SEM. p values were calculated using a two-way ANOVA with a Tukey correction for multiple comparisons.(G) HistoneH3(Ser10)/propidium iodide dual-parameter FACS analysis of KPC primary PDAC cells after treatment with AZD2014 (500 nM) and/or TH-302 (1 μM) at 0.1% oxygen. Mean ± SEM. p values are from a Student two-tailed parametric t test.(H) Schematic representation of the proposed combination effect of AZD2014 on cells prior to mitotic entry by TH-302.^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001.

Mapping of Transient Hypoxic Tumor Regions *In Vivo* {#sec2.5}
----------------------------------------------------

In order to map tumor hypoxia in more detail, we assessed the temporal change in the distribution of hypoxia over a 24-hr period. To track hypoxia, we employed both the GEM and subcutaneous KPC PDAC models, treating with the 2-nitroimidazole hypoxia markers EF5 ([@bib28]) and pimonidazole ([@bib50]). These markers were either co-injected or administered 24 hr apart. As expected, when the probes were co-injected, there was a strong co-localization of the two markers, with a large overlap of the immunofluorescence signals ([Figure 5](#fig5){ref-type="fig"}). Notably, when the EF5 and pimonidazole injections were staggered, 24 hr apart, we observed a distinct shift between the two markers and the overlap of the signals decreased ([Figure 5](#fig5){ref-type="fig"}). This effect was also observed in the KP^fl^C GEM model ([Figure S4](#mmc1){ref-type="supplementary-material"}). Such a significant decrease in overlap in the staggered condition reveals that hypoxia moves transiently around the tumor. Many groups have described the important function of metabolic reprogramming over oxygen gradients, associated with the aberrant vascular networks that give rise to the formation of hypoxia in many cancers ([@bib41], [@bib44]). In such a rapid disease model, it then does not seem surprising that oxygen gradients should move around the tumor. This has important implications for cancer therapies, as the resistance that is associated with the hypoxic compartment may also transit between tumor regions. Fortunately, the use of HAPs, which become more active in these hypoxic regions, allows treatments to effectively hijack this phenomenon to release cytotoxics by a local bystander effect and potentially to reduce the hypoxia-induced resistance we have observed *in vivo*.Figure 5Tracking of Tumor Hypoxia with EF5 and Pimonidazole(A and B) Immunofluorescence of (A) KPC GEM tumors and (B) KPC xenograft tumors for EF5 (red) and pimonidazole (green), chemical indicators of tumor hypoxia, after either (i) co-injection or (ii) 24-hr delayed treatments. Scale bars, 100 μm. (iii) Quantification of overlapping (yellow) regions of staining between EF5 and pimonidazole in KPC GEM tumors (n = 3 mice/group) and KPC xenograft tumors (n = 4 mice/group). Mean ± SEM. p values are from a Student two-tailed parametric t test in all panels.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Development of a Dual Imaging Modality for Parallel Monitoring of PI3K Pathway Activity and Tumor Oxygen Content in Live Cells {#sec2.6}
------------------------------------------------------------------------------------------------------------------------------

Having established the transient nature of the hypoxic gradients within the tumor, we then developed a method for live tracking of both drug response and oxygen content by real-time IVM. In contrast to static readouts, IVM provides a dynamic means to measure single-cell responses within their native microenvironment ([@bib8], [@bib9], [@bib11]). Initially, KPC cells were engineered to stably express the Eevee-Akt-mT2 FRET biosensor, which undergoes a conformational change in response to phosphorylation by Akt at a specific consensus sequence and so an increase in the FRET efficiency, which can be monitored using FLIM-FRET ([Figure S5](#mmc1){ref-type="supplementary-material"}A) ([@bib24]). Expression of this FRET biosensor caused no detectable change in the response of KPC cells to hypoxia, which also demonstrated a similar pattern of resistance for all three PI3K pathway inhibitors ([Figures S5](#mmc1){ref-type="supplementary-material"}B--S5E). Akt is a key effector of the PI3K pathway and is inactivated by AZD2014 through mTORC2 inhibition ([Figure S5](#mmc1){ref-type="supplementary-material"}F) ([@bib10]). Since AZD2014 is weakly autofluorescent, we used an experimentally measured time-varying background (TVB) to account for background fluorescence from the cells and the drug (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for details and validation) ([@bib9]). Using FLIM-FRET imaging, we observed that initial activation of Akt by EGF was reduced by AZD2014, as expected ([Figures S5](#mmc1){ref-type="supplementary-material"}G--S5J). In contrast, treatment with the mTORC1 inhibitor rapamycin had no inhibitory effect on Akt. This is in line with previous reports, where inhibition of mTORC1 alone instead acts to upregulate Akt activity through IRS1 ([@bib36]). Having established the specificity of the Eevee-Akt-mT2 FRET biosensor and the significant response of the biosensor-expressing cells to treatment with AZD2014, we next developed a method for parallel monitoring of oxygen content by dual FLIM/PLIM imaging.

The first step toward our dual imaging modality was to assess the effect of low oxygen levels on the activity of Akt by FLIM-FRET microscopy, and in line with the western blot assessment ([Figures 1](#fig1){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}B), we found a significant increase in Akt activity in hypoxia (1% and 0.1% oxygen) compared to normoxia ([Figure S6](#mmc1){ref-type="supplementary-material"}A). An emerging option for live imaging of tumor oxygen content is through the use of oxygen-sensitive ruthenium, platinum, or iridium complexes as nanoparticles ([@bib9], [@bib21], [@bib25], [@bib56]). Recently, imaging of the intrinsic autofluorescence of NAD(P)H/FAD^+^ was combined with PLIM of an oxygen-sensitive ruthenium complex ([@bib21]). This approach used on-off modulation of the pulsed laser source on a microsecond timescale to allow measurements of the longer oxygen-sensitive phosphorescence decays ([@bib21]). Here, we took a similar approach, using an electro-optic modulator (EOM) to switch a multiphoton laser at low frequency ([Figure 6](#fig6){ref-type="fig"}A). This allowed us to detect both the short FLIM decays (nanosecond scale) from the Eevee-Akt-mT2 biosensor, and the much longer phosphorescence decays (microsecond scale) of an oxygen-sensitive nanoparticle ([Figure 6](#fig6){ref-type="fig"}A).Figure 6Dual FLIM/PLIM Imaging of KPC Cells Stably Expressing the Eevee-Akt-mT2 Intramolecular FRET Biosensor, Treated with Oxygen-Sensitive Nanoparticles(A) A schematic illustration of the methodology applied to modify the multiphoton FLIM detection system to detect oxygen-sensitive PLIM through modulation of the EOM.(B) A schematic demonstrating the use of a glass coverslip to induce a hypoxic response *in vitro*.(C) qRT-PCR analysis of relative mRNA expression of hypoxia response genes upregulated in cells incubated for 2 hr in hypoxia (5%, 1%, and 0.1% oxygen) or under a coverslip, compared to normoxia, normalized to *Rplp0* (n = 5). Mean ± SEM.(D) Dual FLIM/PLIM imaging of Akt activity in KPC cells treated with MitoImage NanO2 and incubated with a glass coverslip for 1 or 2 hr (n = 4). Scale bars, 50 μm; insets, 10 μm. Mean ± SEM. p values are from a Student two-tailed parametric t test in all panels.^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001. See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}, and [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

In order to validate our approach *in vitro*, we placed glass coverslips over KPC cell monolayers to reduce the oxygen concentration ([Figure 6](#fig6){ref-type="fig"}B). First, however, we characterized the application of this coverslip hypoxia induction by staining cells for nuclear HIF1α stabilization and pimonidazole adduct formation, and observed a significant increase in both after 2 hr, equivalent to 0.1% or 1% oxygen incubations ([Figures 6](#fig6){ref-type="fig"}B and [S6](#mmc1){ref-type="supplementary-material"}B; quantified in [Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D). Furthermore, we assessed the response of cells under a coverslip by quantitative real-time PCR (qRT-PCR) for genes characteristically upregulated under hypoxic conditions and found a significant upregulation of *Slc2a1* (GLUT1), *Slc2a3* (GLUT3), *Ldha* (lactate dehydrogenase A), *P4ha2 V1/V2* (prolyl 4-hydroxylase), *Ndrg1*, and *Adm* (adrenomedullin) ([Figure 6](#fig6){ref-type="fig"}C) ([@bib31], [@bib44]). In this way, we could confirm that a 2-hr incubation with a glass coverslip was sufficient to decrease oxygen levels and relieve the oxygen-dependent quenching of MitoImage NanO2, which led to a significant increase in the PLIM ([Figure 6](#fig6){ref-type="fig"}D, top panel; note shift in PLIM from blue to orange/red upon decrease in oxygen content). In parallel, we were able to track the activity of Akt in the same cells by FLIM-FRET microscopy of the Eevee-Akt-mT2 intramolecular FRET biosensor and observed a significant increase in the FRET efficiency, consistent with an increase in Akt activity ([Figure 6](#fig6){ref-type="fig"}D, bottom panel; note shift in FLIM from orange to blue). As an additional confirmation, we treated parental KPC cells with MitoImage MM2, which is composed of an oxygen-sensitive phosphorescent (PtTFPP) and oxygen-insensitive fluorescent (PFO) component that can be read out ratiometrically, to assess oxygen content ([@bib25]). By placing a glass coverslip on these cell monolayers, we observed a significant increase in the ratio of the oxygen-sensitive PtTFPP to the oxygen-insensitive PFO, consistent with a decrease in the oxygen content of the cell monolayer ([Figure S6](#mmc1){ref-type="supplementary-material"}E).

Live Tracking of Tumor Oxygen Content Allows Real-Time Assessment of Drug Response by IVM {#sec2.7}
-----------------------------------------------------------------------------------------

Having established the dual FLIM/PLIM imaging methodology for *in vitro* imaging, we next assessed the effect of the combination therapy on Akt activity in a live setting. Consistent with the tumor growth experiment ([Figure 3](#fig3){ref-type="fig"}), mice were given AZD2014 and TH-302, and once subcutaneous xenografts reached a volume of \>350 mm^3^, where hypoxia is readily observed, tumors were surgically exposed and treated with the oxygen-sensitive nanoparticles ([Figure 7](#fig7){ref-type="fig"}A) ([@bib9], [@bib51]). Assessing single cells for their response to each treatment, we found no significant difference in Akt activity between vehicle and TH-302 treatments, as expected ([Figure 7](#fig7){ref-type="fig"}B, compare black plot to red). Conversely, upon treatment with AZD2014, a significant decrease in Akt activity was recorded ([Figure 7](#fig7){ref-type="fig"}B, compare black plot to blue). Furthermore, when AZD2014 was used in combination with TH-302, Akt activity was significantly reduced to a greater degree than AZD2014 monotherapy ([Figure 7](#fig7){ref-type="fig"}B, compare blue plot to green). This effect was then stratified based on the oxygen content by analyzing the Akt activity of individual cells (FLIM-FRET) and the oxygen content by PLIM ([Figures 7](#fig7){ref-type="fig"}C--7F, top panel, Akt activity \[FLIM-FRET\]; bottom panel, oxygen content \[PLIM\]). In this way, we observed heterogeneity in Akt activity for vehicle and TH-302 treatments, as expected ([Figures 7](#fig7){ref-type="fig"}C and 7D; plotted in [Figures 7](#fig7){ref-type="fig"}G and 7H, respectively). However, we found that cells treated with AZD2014 monotherapy had reduced Akt activity predominantly in the high-oxygen (normoxia) regions and less so in the low-oxygen (hypoxia) regions ([Figure 7](#fig7){ref-type="fig"}E; plotted in [Figure 7](#fig7){ref-type="fig"}I). Importantly, this effect was absent in the combination therapy, where Akt activity was reduced in both high- and low-oxygen regions ([Figure 7](#fig7){ref-type="fig"}F; plotted in [Figure 7](#fig7){ref-type="fig"}J). This confirms and builds upon our *in vitro* findings on hypoxia-induced resistance, prompting further analysis of the *in vivo* effect of oxygen content on drug response.Figure 7Dual FLIM/PLIM Intravital Imaging of Drug Response and Tumor Oxygen Content(A) A schematic representation of the intravital imaging setup for the dual FLIM/PLIM imaging. Xenografts of KPC cells stably expressing the Eevee-Akt-mT2 intramolecular FRET biosensor were allowed to reach 350 mm^3^, before treatment with oxygen-sensitive nanoparticles (NanO2) and dual FLIM/PLIM imaging.(B) FLIM-FRET analysis of vehicle/saline (n = 5), vehicle/TH-302 (n = 4), AZD2014/saline (n = 7), or AZD2014/TH-302 (n = 4)-treated mice. Mean ± SEM. p values are from a Student two-tailed parametric t test.(C--F) Representative FLIM and PLIM maps are provided for cells with a short PLIM value (high oxygen content, normoxic) and a long PLIM value (low oxygen content, hypoxic) for vehicle/saline (C), vehicle/TH-302 (D), AZD2014/saline (E), and AZD2014/TH-302 (F) treatments. Scale bars, 25 μm.(G--J) These same cells are then highlighted on their representative Deming regression curves, where blue and red points highlight cells with short or long PLIM values, respectively. The 95% confidence intervals emphasize whether the slope of the Deming regression is significantly non-zero for vehicle/saline (G), vehicle/TH-302 (H), AZD2014/saline (I), and AZD2014/TH-302 (J) treatments.(K) Average Deming slopes of mice from each treatment group, assessed for departure from zero with a one-sample t test. Mean ± SEM.^∗^p \< 0.05, ^∗∗^p \< 0.01 and ^∗∗∗^p \< 0.001.

In order to quantify the effect of oxygen content on drug response, we plotted the fluorescence lifetime from the Eevee-Akt-mT2 FRET biosensor for Akt activity (FLIM-FRET), against the phosphorescence lifetime of MitoImage NanO2, as a measure of oxygen content (PLIM; [Figures 7](#fig7){ref-type="fig"}G--7J). Using Deming regression curves, to account for the error in both parameters (FLIM-FRET and PLIM), Deming slopes were calculated and plotted with their 95% confidence bands to highlight the quality of the fit ([Figures 7](#fig7){ref-type="fig"}G--7J). For the vehicle treatment, the Deming regression slope was not significantly different from zero, which meant that the error in the slope was sufficiently large and that the confidence in the slope did not exist ([Figure 7](#fig7){ref-type="fig"}G). This was consistent with the heterogeneous Akt activity in both the vehicle and TH-302-treated mice ([Figure 7](#fig7){ref-type="fig"}K, see black and red bars). In the AZD2014 treatment, however, the slope of the regression was negative and significantly non-zero ([Figure 7](#fig7){ref-type="fig"}K, see blue bar). This identified a significant link between increased Akt activity and low oxygen content, demonstrating that, in the AZD2014 treatments, there was hypoxia-induced resistance ([Figure 7](#fig7){ref-type="fig"}I). Cumulative assessment of the AZD2014 treatments confirmed this negative slope was significant, indicating the presence of hypoxia-induced resistance to AZD2014 monotherapy within our live tumors ([Figure 7](#fig7){ref-type="fig"}K). Furthermore, when AZD2014 treatment was combined with TH-302, this resistance was relieved ([Figure 7](#fig7){ref-type="fig"}K, see green plots), consistent with the improved inhibition of Akt for the combination treatments ([Figure 7](#fig7){ref-type="fig"}B). In this way, we have identified hypoxia-induced resistance to PI3K pathway targeting, at the single-cell level, within our live tumors by IVM and successfully alleviated this *in vivo* resistance in combination with the HAP TH-302.

Discussion {#sec3}
==========

Increasingly, our awareness of the context-dependent effects on treatment efficacy, such as microenvironmental factors and the influence of tumor-associated immune or stromal components, is driving the development of more sophisticated IVM approaches to account for these important contributing factors ([@bib9], [@bib11], [@bib20], [@bib51]). PDAC has a well-established hypoxic signature, and this hypoxia was clearly evident in our GEM and subcutaneous mouse models ([@bib6], [@bib31]). Moreover, a hypoxic tumor microenvironment is strongly associated with treatment-refractory disease ([@bib46], [@bib55]), and here we demonstrate hypoxia-induced resistance to three PI3K pathway inhibitors. This occurs in parallel with an increase in the activity of Akt, a key effector of the PI3K pathway. In light of our recent work, demonstrating an equivalent survival benefit for AZD2014, a dual inhibitor of the PI3K pathway, with standard-of-care gemcitabine ([@bib10]), these data provide strong support for investigation into the effects of hypoxia on PI3K pathway targeting.

Given our initial insight into the persistent movement of hypoxic regions throughout the tumor, the ability to track and target this key microenvironmental factor has a clear benefit for pre-clinical investigations aimed at negating the effects of tumor hypoxia. However, few methods exist for live monitoring of hypoxia by IVM and they lack the parallel approach that would be necessary to investigate the effects of hypoxia on therapeutic response ([@bib9]). For whole-tumor assessment, many non-invasive positron emission tomography (PET)-based approaches depend upon the increased glucose uptake of tumors ([@bib14], [@bib39]). Of note, new probes have been developed to provide information on the hypoxic content of tumors, based on CAIX expression or 2-nitroimidazoles, primarily to guide hypoxia-targeted treatment strategies ([@bib14], [@bib19], [@bib39]). However, for molecular assessment during preclinical drug development, a new approach was necessary to overlay tumor oxygen content with therapeutic response by IVM. On the one hand, genetic markers based on the oxygen degradation domain or hypoxia-response elements of HIF1α are common ([@bib12], [@bib53]), but these may encounter hurdles for interpretation due to the dysregulation of the hypoxic response in many cancers and the necessity to measure changes in intensity, instead of a switch-like response. On the other hand, many injectable fluorescent probes exist for tracking various aspects of tumor hypoxia ([@bib35], [@bib48], [@bib56]). In this work, application of oxygen-sensitive nanoparticles for dual FLIM/PLIM imaging facilitated live tracking of drug response in the context of tumor oxygen content. Critically, we identified an oxygen-dependent resistance effect, at the single-cell level, when treating tumors with AZD2014 monotherapy. This effect was reduced *in vivo*, when AZD2014 was combined with the HAP TH-302, leading to improved inhibition of tumor growth. TH-302 alone, or in combination with AZD2014, resulted in a decreased hypoxic fraction, HIF1α and CAIX expression. This reduction in tumor hypoxic response was associated with a concomitant reduction in overall resistance to PI3K pathway targeting and provides a possible explanation for the improved reduction in Akt activity in the combination therapies.

Preclinical IVM experiments can provide a robust method to assess combination therapies aimed at reducing resistant populations and improving therapeutic responses. This possibility has yet to be fully exploited for the known hypoxia-induced resistance to targeted therapeutics aimed at tyrosine kinase, HER2, and VEGF pathways ([@bib2], [@bib3], [@bib22]), as well as chemotherapies ([@bib44], [@bib46]), and highlights the clinical need to track and understand this hypoxia-induced resistance. Intramolecular FRET biosensors already exist to read out the activity of many of these pathways, while the development of simplified backbones for fluorescent protein reporters or FRET biosensors provides a rapid approach to develop readouts for therapeutic response within a live tumor context ([@bib8], [@bib9], [@bib24]). As demonstrated here and elsewhere, the addition of HAPs as a combination therapy provides a suitable approach to reduce the resistant effects of hypoxia with reduced additive toxicity ([@bib34], [@bib55]). By applying IVM using fluorescent protein reporters or FRET biosensors and parallel imaging of tumor hypoxia, the benefits observed here for targeting of the PI3K pathway, in combination with HAPs, can be applied to develop combination therapies with robust preclinical validation.

Experimental Procedures {#sec4}
=======================

Animal Experiments {#sec4.1}
------------------

All animal experiments were conducted in compliance with Garvan Ethics Committee guidelines (13/17 and 16/13 protocols) and in accordance with the Australian code of practice for the care and use of animals for scientific purposes, with genotyping performed by Garvan Molecular Genetics (Sydney, NSW, Australia). Both male and female KP^fl^C and KPC GEM were monitored for swollen abdomen, cachexia, and reduced mobility until tumor was evident by palpation, and hypoxia markers were administered ([@bib17], [@bib18], [@bib33]). For xenografts experiments, 1 × 10^6^ KPC primary PDAC cells in PBS were subcutaneously injected into the rear flank of 6- to 10-week-old female BALB/c-Fox1nuAusb mice.

FACS {#sec4.2}
----

Cells were fixed in 70% ethanol, prior to staining with propidium iodide (Sigma-Aldrich; P4170; 1 μg/mL) with RNaseA (Sigma-Aldrich; R6513; 500 μg/mL), and analysis on a FACSCanto II (BD Biosciences). Quantification was performed in FlowJo (Tree Star), and cell cycle phase was determined in ModFit (Verity Software House).

Intravital FLIM/PLIM Imaging {#sec4.3}
----------------------------

Xenografts of KPC cells expressing the Eevee-Akt-mT2 FRET biosensor were imaged at a final volume of 350 mm^3^, as per the tumor growth studies. Mice were anesthetized with xylazine (10 mg/kg) and Zoletil (50 mg/kg) and kept on a heated stage at 37°C. Anesthesia was maintained with isoflurane (3 L; O~2~, 1 L; vacuum, 1 L/min). Tumors were surgically exposed, as described previously ([@bib9], [@bib51]), prior to application of MitoImage NanO2 (10 μg; Ibidi; 74151). After 30 min, dual FLIM/PLIM imaging was performed on a Leica SP8 microscope with a 0.95 numerical aperture (NA), 25× water objective. Analysis of FLIM and PLIM decays was performed in FLIMfit ([@bib54]) and is presented as mean lifetime per cell.

Organotypic Assay {#sec4.4}
-----------------

Organotypic matrices were generated as described previously ([@bib8], [@bib33], [@bib51]). Quantification of the invasive and proliferative indices was performed on pan-cytokeratin (excludes fibroblasts) or Ki67-stained sections, respectively.

IC~50~ Curves {#sec4.5}
-------------

IC~50~ curves were performed in a 96-well plate format, with 1,000 cells/well. Cells were incubated for 24 hr after seeding before addition of inhibitors. Plates were assessed for relative cell density using the CellTiter 96 AQueous Cell Proliferation Assay (Promega; G1111) at 72 hr after addition of each inhibitor, with parallel plates incubated under standard normoxic or hypoxic (0.1% oxygen) conditions. IC~50~ curves were then fit in Prism (GraphPad Software), normalizing to the vehicle (DMSO) control treatments from the respective normoxic or hypoxic (0.1% oxygen) conditions.

Statistical Analysis {#sec4.6}
--------------------

Statistical tests were performed in Prism (GraphPad Software) with statistical significance given as ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001 in all cases. A one-sample t test was performed on normalized data. For IC~50~ curve comparisons, an extra sum-of-squares F test was performed between the best-fit parameters of each curve. Deming regression curves for the dual FLIM/PLIM analysis were plotted with the "mcr" package of R, using the analytical method to calculate the 95% confidence intervals. To assess whether the Deming regression slopes were significantly non-zero, a one-sample t test was performed. DNA cell cycle analysis was assessed for significance using a two-way ANOVA test with a Tukey correction for multiple comparisons. In all other cases, a Student two-tailed parametric t test was performed.

Detailed protocols can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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